DelveInsight’s “Graft versus host Disease Market Insights, Epidemiology and Market Forecast–2034” report delivers an in-depth understanding of Graft-versus-host Disease, historical and forecasted epidemiology as well as the Graft-versus-host Disease market trends in the US, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Discover Key Insights into the Graft Versus Host Disease Market with DelveInsight’s In-Depth Report @ Graft Versus Host Disease Market Size

 

Key Takeaways from the Graft Versus Host Disease Market Report

• In November 2024:-Chia Tai Tianqing Pharmaceutical Group Co., Ltd.- A Randomized, Open Label, Positive Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of the Selected Regimen of Rovadicitinib in Moderate to Severe Chronic Graft-versus-host Disease in Third Line and Beyond
• In November 2024:- Incyte Corporation- A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease. This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.
• In the US, the total hematopoietic stem-cell and allogenic transplant cases were ~25,000 and ~10,500, respectively, in 2023.
• The US contributed to the largest Graft vs. Host Disease population, acquiring ~45% of the 7MM in 2023. Japan accounted for around 16% and Germany accounted for around 15% of the total population share, respectively, in 2023.
• The overall severity of chronic graft-versus-host disease (GvHD) is classified as mild, moderate, or severe based on organ-specific grading (number of organs and severity). Approximately ~45% of five year prevalent cases of chronic condition belong to the moderate category.
• As per DelveInsight’s estimates, In 2023, approximately 50% of cases of acute graft –versus-host disease were treated first-line in Japan.
• The leading Graft Versus Host Disease Companies such as Equillium, Biocon, Takeda, CSL Behring, Regimmune Corporation, Syndax Pharmaceutical, Mesoblast, JCR Pharmaceuticals, Incyte Corporation, Pfizer, Bristol-Myers Squibb, Roche-Genentech, Genentech, Inc., VectivBio AG, Seres Therapeutics, Inc., and others
• Promising Graft Versus Host Disease Therapies such as EQ001 (itolizumab; Bmab600), ENTYVIO (vedolizumab), ZEMAIRA (CSL 964, alpha-1 antitrypsin), RGI-2001 (KRN-7000; RGI-7000), SNDX-6352 (axatilimab), RYONCIL/TEMCELL HS (remestemcel-L), Itacitinib, Glasdegib, Abatacept, Obinutuzumab, GDC-8264, Apraglutide, SER-155, and others.

 

Stay ahead in the Graft Versus Host Disease Therapeutics Market with DelveInsight’s Strategic Report @ Graft Versus Host Disease Market Outlook

 

Graft Versus Host Disease Epidemiology Segmentation in the 7MM

• Total Hematopoietic Stem-cell Transplant Cases
• Total Allogeneic Transplant Cases
• Total GvHD Cases by Types
• Total Incident Cases of aGvHD by Grading and Organ Involvement
• Total Five-Year Prevalent Cases of cGvHD by Severity and Organ Involvement
• Total Treated Patients of GvHD
• Mortality Adjusted GvHD Treated Patients

 

Download the report to understand which factors are driving Graft Versus Host Disease epidemiology trends @ Graft Versus Host Disease Prevalence

 

Graft versus Host Disease Marketed Drugs

• JAKAFI / JAKAVI (ruxolitinib): Incyte Corporation/ Novartis

Ruxolitinib, a kinase inhibitor, inhibits Janus Associated Kinases (JAKs) JAKl, and JAK2, which mediate the signaling of some cytokines and growth factors important for hematopoiesis and immune function. JAK signaling involves the recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation, and subsequent localization of STATs to the nucleus leading to modulation of gene expression.

 

• IMBRUVICA (ibrutinib): Pharmacyclics (acquired by AbbVie)/ Janssen

IMBRUVICA (ibrutinib) is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton’s tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell receptor signaling complex that plays an important role in the survival and spread of malignant B cells and other serious, debilitating conditions.

 

Graft versus Host Disease Emerging Drugs

 

• ZEMAIRA (CSL 964, alpha-1 antitrypsin): CSL Behring

CSL964 Alpha-1Antitrypsin is an Alpha1-Proteinase Inhibitor (A1 -PI) being developed by CSL Behring to treat steroid-refractory, aGvHD and prevention of aGvHD in high-risk patients receiving an allogeneic HSCT. Currently, it is being investigated in Phase III (NCT04167514) clinical studies for the treatment of high-risk acute GVHD as a first-line therapy option and a Phase II/III (NCT03805789) study for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant.

 

• EQ001 (itolizumab; Bmab600): Equillium/Biocon

EQ001 (Itolizumab; Bmab600) is a first-in-class immune-modulating antibody therapeutic designed to inhibit CD6 to reduce the activation and trafficking of pathogenic T cells that release pro-inflammatory cytokines of autoimmune and inflammatory diseases like aGvHD, uncontrolled moderate-to-severe asthma, and lupus nephritis. Itolizumab targets the CD6-ALCAM signaling pathway to selectively down-regulate pathogenic effector T cells (Teff) while preserving Treg cells critical for maintaining a balanced immune response.

 

Get In-Depth Knowledge on Graft Versus Host Disease Market Trends and Forecasts with DelveInsight @ Graft Versus Host Disease Treatment Market

 

Graft Versus Host Disease Therapeutics Market Landscape

IncyteCARES is a financial assistance program provided by the Incyte Corporation for JAKAFI, to help the patient get started with the medicine and provide information and resources throughout the treatment. The Graft versus Host Disease drug market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

 

Graft Versus Host Disease Therapies and Companies

• EQ001 (itolizumab; Bmab600): Equillium/Biocon
• ENTYVIO (vedolizumab): Takeda
• ZEMAIRA (CSL 964, alpha-1 antitrypsin): CSL Behring
• RGI-2001 (KRN-7000; RGI-7000): Regimmune Corporation
• SNDX-6352 (axatilimab): Syndax Pharmaceutical
• RYONCIL/TEMCELL HS (remestemcel-L): Mesoblast/JCR Pharmaceuticals
• Itacitinib: Incyte Corporation
• Glasdegib: Pfizer
• Abatacept: Bristol-Myers Squibb
• Obinutuzumab: Roche-Genentech
• GDC-8264: Genentech, Inc.
• Apraglutide: VectivBio AG
• SER-155: Seres Therapeutics, Inc.

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Graft Versus Host Disease Market Report @ Graft Versus Host Disease Market Drivers and Barriers

 

Scope of the Graft Versus Host Disease Market Report

• Coverage- 7MM
• Graft Versus Host Disease Companies- Equillium, Biocon, Takeda, CSL Behring, Regimmune Corporation, Syndax Pharmaceutical, Mesoblast, JCR Pharmaceuticals, Incyte Corporation, Pfizer, Bristol-Myers Squibb, Roche-Genentech, Genentech, Inc., VectivBio AG, Seres Therapeutics, Inc., and others
• Graft Versus Host Disease Therapies- EQ001 (itolizumab; Bmab600), ENTYVIO (vedolizumab), ZEMAIRA (CSL 964, alpha-1 antitrypsin), RGI-2001 (KRN-7000; RGI-7000), SNDX-6352 (axatilimab), RYONCIL/TEMCELL HS (remestemcel-L), Itacitinib, Glasdegib, Abatacept, Obinutuzumab, GDC-8264, Apraglutide, SER-155, and others.
• Graft Versus Host Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Graft Versus Host Disease Unmet Needs, KOL’s views, Analyst’s views, Graft versus Host Disease Market Access and Reimbursement

 

Table of Content

1. Key Insights

2. Report Introduction

3. Graft-versus-host disease (GvHD) Market Overview at a Glance

4. Executive Summary of Graft-versus-host Disease

5. Key Events

6. Disease Background and Overview

7. Current Treatment

8. Epidemiology and Market Methodology

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Therapies

12. Emerging Therapies.

13. GvHD Market Analysis: The US, EU4 and the UK, and Japan

14. KOL Views.

15. SWOT..

16. Unmet needs

17. GvHD Market Access and Reimbursement

18. Appendix.

19. DelveInsight Capabilities

20. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/in-licensing-opportunity